Upadacitinib

證據等級: L5

預測適應症: 2 個

Upadacitinib: From Unspecified Original Indication to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

One-Sentence Summary

Upadacitinib is a JAK1-selective inhibitor; its original approved indication is not available in this evidence pack, and the drug is not currently marketed in Norway. The TxGNN model predicts a possible association with colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare congenital developmental disorder, but this prediction is supported by no clinical trials and no published literature — it is a statistical model output only.

Quick Overview

Item	Content
Original Indication	Not available (no license or indication data in this evidence pack)
Predicted New Indication	Colobomatous microphthalmia-rhizomelic dysplasia syndrome
TxGNN Prediction Score	99.61%
Evidence Level	L5
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack beyond the drug class designation. Based on known information, upadacitinib is a JAK1-selective inhibitor whose established pharmacology involves suppression of cytokine-mediated inflammatory signaling.

The predicted indication, colobomatous microphthalmia-rhizomelic dysplasia syndrome, is a rare congenital structural/developmental syndrome (ocular coloboma with proximal limb skeletal dysplasia), driven by developmental gene mutations rather than inflammatory or autoimmune pathology. The evidence pack's own repurposing rationale states there is no established biological connection between JAK1 inhibition and this congenital malformation mechanism — the prediction score reflects only a graph-neural-network statistical association, not a mechanistically grounded hypothesis.

A second, similarly ranked prediction (brachydactyly-syndactyly syndrome, score 99.58%) shows the same pattern: a congenital skeletal malformation syndrome with no known relationship to JAK1-mediated anti-inflammatory activity. Both predictions should be treated as exploratory signals only, not as candidates with plausible mechanistic support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

This drug is not currently marketed in Norway (0 authorizations on record); no product license data is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is evidence level L5 (model output only, no clinical trials or literature), and the evidence pack's own mechanistic rationale explicitly finds no plausible biological link between JAK1 inhibition and this congenital developmental syndrome. There is no basis to advance this candidate at this time.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for upadacitinib from DrugBank or the manufacturer's product information
TFDA/regulatory label data on warnings and contraindications (currently blocking per DG001)
An independent biological plausibility review, since the automated rationale itself argues against a mechanistic connection
If plausibility cannot be established, this candidate should be deprioritized in favor of higher-scoring, mechanistically coherent predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.